The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple ...

Neoadjuvant immunotherapy combined with chemotherapy shows promising results in treating limited-stage small cell lung cancer ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative treatments reshaping cancer care for patients and clinicians alike.

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high ...

Fertility preservation becomes crucial for reproductive-age cancer patients, emphasizing timely intervention and ...

Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced ...

New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...